Omeros Corporation stock is up 103.97% since 30 days ago. The next earnings date is Mar 11, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 53.33% of the previous 14 December’s closed higher than November. In the last 5 Unusual Options Trades, there were 5 PUTs. 0% of analysts rate it a buy.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|16 Oct 13:30||20 Oct, 2023||3.00||2740|
|16 Oct 14:43||20 Oct, 2023||3.00||2740|
|16 Oct 14:53||19 Jan, 2024||5.00||1299|
|30 Nov 14:30||19 Jan, 2024||5.00||1065|
|30 Nov 14:30||19 Jan, 2024||8.00||111|
Omeros Corporation discovers, develops, and commercializes small-molecule and protein therapeutics. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and atypical hemolytic uremic syndrome (aHUS) The company was incorporated in 1994 and headquartered in Seattle, Washington.